A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Interleukin 12 ◽

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

Frontiers in Pharmacology ◽

10.3389/fphar.2017.00263 ◽

2017 ◽

Vol 8 ◽

Cited By ~ 5

Author(s):

Iraida Caballero

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Dose Escalation ◽

Phase I Study ◽

Growth Factor Receptor ◽

Castration Resistant ◽

Faculty of 1000 evaluation for Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718203593.793488507 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer

Molecular and Clinical Oncology ◽

10.3892/mco.2017.1176 ◽

2017 ◽

Vol 6 (4) ◽

pp. 534-538 ◽

Cited By ~ 1

Author(s):

Kenji Tezuka ◽

Tsutomu Takashima ◽

Shinichiro Kashiwagi ◽

Hidemi Kawajiri ◽

Shinya Tokunaga ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14346.471799 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Irreversible Inhibitor ◽

A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas

Neurosurgery ◽

10.1097/00006123-199609000-00009 ◽

1996 ◽

Vol 39 (3) ◽

pp. 478-483 ◽

Cited By ~ 11

Author(s):

Thierry Faillot ◽

Henri Magdelénat ◽

Essam Mady ◽

Paul Stasiecki ◽

Denis Fohanno ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Malignant Gliomas ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Receptor Monoclonal Antibody

A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3018 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3018-3018 ◽

Cited By ~ 5

Author(s):

T. Trarbach ◽

T. Beyer ◽

N. Schleucher ◽

J. Stattaus ◽

S. P. Mueller ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Gastrointestinal Cancers ◽

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3061 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3061-3061

Author(s):

U. Graeven ◽

I. Vogel ◽

B. Killing ◽

S. Hinz ◽

W. Von Bernstorff ◽

...

Keyword(s):

Pancreatic Cancer ◽

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Advanced Pancreatic Cancer ◽

Growth Factor Receptor ◽

552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90584-2 ◽

2003 ◽

Vol 1 (5) ◽

pp. S167 ◽

Cited By ~ 3

Author(s):

C. Delbaldo ◽

J.Y. Pierga ◽

V. Dieras ◽

S. Faivre ◽

M. Bonnay ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies

The Oncologist ◽

10.1634/theoncologist.2008-0124 ◽

2009 ◽

Vol 14 (2) ◽

pp. 119-124 ◽

Cited By ~ 15

Author(s):

Michael J. Guarino ◽

Charles J. Schneider ◽

Martha A. Hosford ◽

Julie R. Brahmer ◽

Charles M. Rudin ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Solid Malignancies ◽

Epidermal Growth ◽

Dual Inhibition

A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor

Nuclear Medicine Communications ◽

10.1097/00006231-200212000-00002 ◽

2002 ◽

Vol 23 (12) ◽

pp. 1155-1164 ◽

Cited By ~ 20

Author(s):

K. A. VALLIS ◽

R. M. REILLY ◽

P. CHEN ◽

A. OZA ◽

A. HENDLER ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽